Efficacy of noofen use in the treatment of gastroesophageal reflux disease in schoolchildren

• Main Authors: S.L. Nyankovskyy, M.I. Horodylovska, V.A. Ivantsiv, O.I. Boyko
• Format: Article
• Language: English
• Published: Publishing House Zaslavsky 2017-03-01
• Series: Zdorovʹe Rebenka
• Subjects: gastroesophageal reflux disease; autonomic dysfunction; schoolchildren; Noofen
• Online Access: http://childshealth.zaslavsky.com.ua/article/view/101405

We examined 40 children aged 10–18 years, who were diagnosed with gastroesophageal reflux disease (GERD). According to a survey by O.M. Vein, all patients had manifestations of autonomic dysfunction. The children were divided into 2 groups. The control group consisted of 20 patients, who received standard antisecretory therapy. The main group consisted of 20 children, who received standard antisecretory therapy and phenibut (Noofen®, OlainFarm, Latvia) at a dose of 250 mg 2 times a day for 21 days. After 1 month of starting the treatment, an evaluation of its efficacy was conducted. Clinical evaluation of the dynamics of autonomic nervous system status in schoolchildren with GERD suggests that inclusion of Noofen into the complex of therapy for this disease provides good stabilizing effect, which manifests by a restoration of autonomic nervous system balance in schoolchildren.